Praxis Precision Medicines: H.C. Wainwright reaffirms buy recommendation with target of 1201 USD and praises CNS therapies
Reading Time: 3 minutes
Praxis Precision Medicines (PRAX) focuses on targeted precision medicine for the treatment of central nervous system diseases. H.C. Wainwright reiterates a buy recommendation with a target price of $1,201 due to upcoming approval decisions. The management is currently concentrating on transitioning from clinical development to the commercial phase. Precision Medicine for the Central Nervous System The business model of Praxis Precision Medicines (PRAX) is based on the development of targeted therapies for the central nervous system. The...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
